Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrowRelated Article
NEUROLOGY 2006;66:297
© 2006 American Academy of Neurology

February 14 Highlight and Commentary

Use of rt-PA in a statewide acute stroke registry

Deng et al. found that among 2,566 acute stroke admissions to 16 statewide hospitals, 12.9% were eligible for rt-PA treatment. Of these, 13% received treatment. Treatment rate was better in men and in patients treated by emergency medical services. The primary reasons for nontreatment were delayed presentation and unknown onset time.

see page 306

Understanding chaos and the transformation of acute stroke care

Commentary by David S. Liebeskind, MD

During the minutes immediately following stroke onset, there may be dramatic changes in clinical symptoms ranging from rapid resolution of disabling deficits to sudden neurologic deterioration. Dynamic fluctuations in acute stroke pathophysiology may be characterized by chaos theory, where complex changes and instability may be determined by potentially predictable specific underlying factors. Initial patient encounters as early as 20 minutes after stroke onset in the FAST-MAG Phase 3 trial underscores these very early dynamic phases.1 The mounting extent of brain injury across individuals makes it imperative to diagnose and treat as early as possible, even if such an approach results in a large percentage of emergently triaged TIA (figure) cases. Such chaos during early stages allows for dramatic reversal of a devastating disorder.


Figure 11
Figure. Spontaneous clinical improvement and recanalization of transient right middle cerebral artery occlusion associated with resolution of diffusion-weighted imaging abnormality between images acquired at 1 hour (left) and 4 hours (right) after symptom onset.

The Deng et al. study assessed the use of IV tissue plasminogen activator (tPA) in a statewide registry and identified factors associated with tPA use in eligible cases, pointing to the need for improved public education, rapid triage, and associated documentation in acute stroke. Paramedic transport, documentation of time of onset, and earlier presentation within the narrow 3-hour window were associated with increased use of tPA. Time was an essential, pervasive component in nearly all analyses. A large percentage of TIA cases was also noted in those not receiving tPA, an expected result when one targets the early dynamic phases of acute stroke. This realistic perspective on the relatively chaotic nature of acute stroke care in clinical practice reflects the Michigan experience, yet similar approaches may be used to identify important variables and patterns in other regions.

Understanding the chaos inherent in acute stroke pathophysiology and complex association with time as a pivotal variable is not limited to tPA, and is likely to affect future treatment options including strategies for intracranial hemorrhage.2 Early and appropriate intervention will depend on adapting current models of stroke care delivery to the chaotic nature of stroke and its management in clinical practice across a diverse range of settings.

see page 306

References

  1. Field Administration of Stroke Therapy—Magnesium (FAST-MAG) Trial. Available at: http://www.clinicaltrials.gov/ct/show/NCT00059332?order=1. Accessed December 20, 2005.
  2. Mayer SA, Brun NC, Begtrup K, et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777–785.[Abstract/Free Full Text]

Related Article

IV tissue plasminogen activator use in acute stroke: Experience from a statewide registry
Y. Z. Deng, M. J. Reeves, B. S. Jacobs, G. L. Birbeck, R. U. Kothari, S. L. Hickenbottom, A. J. Mullard, S. Wehner, K. Maddox, A. Majid for the Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators
Neurology 2006 66: 306-312. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS